PATENT CLAIM ANALYSIS

Application Number: 15751169
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.

Claim (Index 16):
A humanized anti-CCR7 antibody comprising the hypervariable regions HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3, wherein:\n HVR-H1 comprises SEQ ID NO: 6; HVR-H2 H1 comprises SEQ ID NO: 13; HVR-H3 H1 comprises SEQ ID NO: 19; HVR-L1 H1 comprises SEQ ID NO: 27; HVR-L2 H1 comprises SEQ ID NO: 31; and HVR-L3 H1 comprises SEQ ID NO: 36, and wherein antibody has at least one of:\n a) a minimal affinity for a synthetic antigen with the amino acid sequence of SEQ ID NO: 76, defined by a Kd that is not more than a factor 10 higher than the Kd of a mouse anti-CCR7 antibody of which the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 1 and of which the amino acid sequence of the light chain variable domain is SEQ ID NO: 2; and, \n b) an IC50 of no more than 100 nM for inhibiting at least one of CCR7-dependent intracellular signalling and CCR7 receptor internalization, by at least one CCR7-ligand selected from CCL19 and CCL21.

Metadata:
- Claim Count in Document: 92.0
- Percentile: 88.0
- Lexical Diversity: 1.8
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15756043', '14673792', '15182327', '15399122', '15505064']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7083704593300559
- 35 USC 102 Novelty (BERT): 0.5424273115496336
- Combined Prediction Score: 0.6917761445520137
- Mean Citation Score: 378.784036
- Max Citation Score: 384.58862
- Similarity Product: 262.68180926766155

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test